Setting new standards in information exchange for the pharmaceutical and biotech industry
IO360 Speaking Faculty Launch Collaboration on Cancer Neoantigens
December 1, 2016
Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) recently announced a major collaboration focused on cancer neoantigens to accelerate the discovery of personalized cancer immunotherapies.
“We’re proud to join the Parker Institute in this collaboration, which demonstrates the vital role that nonprofits can play in bringing together stakeholders from across sectors to work alongside one another to advance the field of cancer immunotherapy,” said Jill O’Donnell-Tormey, PhD, IO360° speaker and Cancer Research Institute CEO and director of scientific affairs.
Dr Ramy Ibrahim, Vice President and Head of R&D for the Parker Institute will be joining Dr Jill O’Donnell-Tormey at the 3rd annual Immuno-Oncology 360° (IO360°) conference where both deliver talks on trends and collaborations in the IO space.
To read more on the collaboration, click here.
For more information on Immuno-Oncology 360°, click here.